

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Genoveffa Franchini et al.	Examiner:	Jeffrey S. Parkin
Serial No.:	10/048,072	Group Art Unit:	1648
Filed:	January 25, 2002	Docket:	1662.018US1
Title:	Immunotherapy In HIV Infected Persons Using Vaccines After Multi-Drug Treatment		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(c)(2), Applicants hereby authorize the Commissioner to charge the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p), to Deposit Account No. 19-0743. Please charge any additional fees or credit any overpayment to Deposit Account No. 19-0743.

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications, and Non-Published Applications identifiable by USPTO Serial Number, are no longer required to be provided to the Office. Notification of this change to this effect was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004 and October 19, 2004. Thus, Applicant has not included copies of any US Patents or US Patent

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Serial No :10/048,072

Filing Date: January 25, 2002

Title: Immunotherapy In HIV Infected Persons Using Vaccines After Multi-Drug Treatment

Page 2

Dkt: 1662.018US1

Applications identifiable by serial number that may be cited with this submission. Should the Office require copies to be provided, Applicant respectfully requests that notice of such requirement be directed to Applicant's below-signed representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

Respectfully submitted,

GENOVEFFA FRANCHINI ET AL.

By their Representatives,


SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938

Minneapolis, MN 55402

(516) 795-6820

Date 3/28/2007

By / 
Robin A. Chadwick
Reg. No. 36,477

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being filed using the USPTO's electronic filing system EFS-Web, and is addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 28th day of March 2007.

KIMBERLY BROWN
Name


Signature

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number 10/048,072**Filing Date** January 25, 2002**First Named Inventor** Franchini, Genoveffa**Group Art Unit** 1648**Examiner Name** Parkin, Jeffrey

Sheet 1 of 1

Attorney Docket No: 1662.018US1**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BELSHE, R. , et al., "Support for the RV144 HIV vaccine trial.", <u>Science</u> , 305(5681), (July 9, 2004),177-80	
		CORREA, R. , et al., "Functional patterns of HIV-1-specific CD4 T-cell responses in children are influenced by the extent of virus suppression and exposure", <u>AIDS</u> , 21(1), (2007),23-30	
		GOMEZ, C. E., et al., "Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C", <u>Vaccine</u> , 25(11), (2007),1969-92	
		GOMEZ, C. E., et al., "Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1IIIB Gag-Pol-Nef proteins of clade B", <u>Vaccine</u> , In Press, <u>Corrected Proof</u> , Available online 16 October 2006,(2006),	
		JACOBSON, J. M., et al., "Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068", <u>J Infect Dis.</u> , 194(5), (2006),623-32	
		JEFFERYS, R. , et al., "Outstanding questions on HIV vaccine trial", <u>Science</u> , 305(5681), (July 9, 2004),180	
		JILEK, S. , et al., "CSF enrichment of highly differentiated CD8+ T cells in early multiple sclerosis", <u>Clinical Immunology</u> , 123(1), (2007),105-113	
		KILBY, J. , et al., "A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).", <u>The journal of Infectious Diseases</u> , 194(12), (2006),1672-6	
		PAL, R. , et al., "Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels.", <u>J Virol.</u> , 80(8), (Apr., 2006),3732-42	
		PETERS, BARRY S., et al., "Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity", <u>Vaccine</u> , 25(11), (2007),2120-2127	
		TRINVUTHIPONG, C. , "Thailand's Prime-Boost HIV Vaccine Phase III", <u>Science</u> , 303(5660), (Feb. 13, 2004),954-5	

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached